Abstract: The present disclosure provides conjugate structures and hydrazinyl-pyrrolo compound structures used to produce these conjugates. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.

Abstract: The present disclosure provides conjugate structures (e.g., polypeptide conjugates) and hydrazinyl-indole compounds used to produce these conjugates. The disclosure also provides methods of production of such conjugates, as well as methods of using the same.

Abstract: The technology relates in part to methods for controlling the activity or elimination of therapeutic cells using multimerization of proteins to manipulate individual protein-protein interactions in therapeutic cells, for example, by activating or eliminating cells used to promote engraftment, to treat diseases or condition, or to control or modulate the activity of therapeutic cells that express chimeric antigen receptors or recombinant T cell receptors.

Abstract: The technology relates in part to methods for controlling elimination of therapeutic cells, for example, cells that express a chimeric antigen receptor. The technology further relates to a two-step method of controlling destruction of therapeutic cells in a patient following an adverse event. The two-step system may include a rapamycin or rapamycin analog-based level of control and a second, rimiducid, level of control. The technology also relates in part to methods for cell therapy using cells that express the inducible caspase polypeptide and the rapamycin-sensitive polypeptide, where the proportion of therapeutic cells eliminated by apoptosis is related to the choice and amount of the administered ligand.

Abstract: The technology relates in part to methods for inducing partial apoptosis of cells that express an inducible caspase polypeptide. The technology further relates in part to methods for inducing partial apoptosis of cells that express an inducible modified caspase polypeptide, having a modified dose response curve to the multimeric ligand inducer. The technology also relates in part to methods for cell therapy using cells that express the inducible caspase polypeptide or the inducible modified caspase polypeptide, where the proportion of caspase polypeptide-expressing cells eliminated by apoptosis is related to the administered amount of the multimeric ligand inducer.

Abstract: In various embodiments, methods and systems for maintaining compatibility between applications, based on feature-set constraints are provided. A distributed computing system provides Platform as a service (PaaS) including a software framework in a service model of cloud computing. A known compatibility baseline is established for features of a first application and a second application. The known compatibility baseline inherently includes a baseline set of unenumerated features of the applications. It is determined that the first application is compatible with second application based on comparing an explicit enumeration of added features or removed features in a feature set of the applications. The added features or removed features are tracked after the baseline set of unenumerated features is defined. The determination whether the first application and the second application are compatible is communicated for processing the first application and/or the second application.

Abstract: The present disclosure provides conjugate structures (e.g., polypeptide conjugates) and hydrazinyl-indole compounds used to produce these conjugates. The disclosure also provides methods of production of such conjugates, as well as methods of using the same.

Abstract: A single-use nesting cup for use with mechanical comminution devices having a spinning drive mechanism for pulverizing pills into powder is disclosed. Each cup has a textured base surface that provides for a more efficient grinding and crushing of pills inserted between two such cups when an upper cup is spinningly brought to bear down on a bottom cup. The textured surface of each cup base has a symmetric three-dimensional wave design with each wave arcing along a curve from an outer cylindrical wall of the cup spiraling in toward a center point of the base of each cup. The crest and troughs of each wave act as grinding edges while the overall symmetric wave design acts to maintain the one or more pills and it's powdered form in the center of the bottom cup.

Abstract: A method includes determining a network requirement for at least one application, dynamically determining a link suitable for data transmission in accordance with a policy based at least in part on a current network condition to meet the network requirement and routing one or more application network data flows associated with the at least one application over the link.

Abstract: A method includes detecting a data flow and an associated originating interface on a network, determining a first link over which to forward the data flow, transmitting the data flow over the determined link, receiving a return data flow and moving a forward direction of the return data flow to a new path if the return data flow arrived via a link other than the first link, wherein all packets following a first packet on the flow are forwarded on the same path as the first packet.

Abstract: A method includes allocating an identifier to each of a plurality of policies each comprising a network-isolation identifier associated with a VXWAN directive and transmitting each of the plurality of policies to one or more devices in a network.

Abstract: A method includes generating at a multi-tenant controller on a network a common shared secret for establishing a link between a first site and a second site, transmitting the shared secret to each of the first site and the second site over a secured channel, assigning a wall clock based start and end validity period for the shared secret, sending the shared secret with a future validity to allow secure link communication to continue if one or more elements in both sites cannot communicate with the multi-tenant controller and using a separate shared secret per link per VXWAN.

Abstract: The technology relates generally to the field of immunology and relates in part to methods for activating T cells and other cells resulting in an immune response against a target antigen. The technology also relates to costimulation of therapeutic cells that express chimeric antigen receptors that recognize target antigens using chimeric MyD88- and CD40-derived polypeptides. The technology further relates in part to therapeutic cells that express chimeric antigen receptors, wherein the chimeric antigen receptors have an endodomain that includes MyD88- and CD40-derived polypeptides, and methods for treating patients using the modified therapeutic cells.

Abstract: The technology relates generally to the field of immunology and relates in part to methods for activating cells, including for example T cells and T cells that express chimeric antigen receptors, using an inducible chimeric polypeptide including CD40, MyD88, or CD40 and MyD88 polypeptides. The technology further relates in part to therapeutic methods for inducing an immune response and treating tumors in a patient.

Abstract: The present disclosure provides conjugate structures and compound structures used to produce these conjugates. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.

Abstract: The present disclosure provides anti-HER2 antibody-maytansine conjugate structures. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.

Abstract: An embodiment of the invention provides a method for multi-tenant enabling a service, where the service includes a plurality of service components. Rules are received from a provider of the service, wherein the rules include rules for isolating the service components and rules for sharing the service components. The service components are matched with virtualization environments and/or physical environments based on the rules. The virtualization environments include at least one isolation container and/or at least one shared container. The service components are stored in the virtualization environments and/or the physical environments based on the matching. The service components are mapped to the at least one isolation container of the virtualization environments, the at least one shared container of the virtualization environments, and/or the physical environments based on the storing of the service components.

Abstract: Speech recognition models are dynamically re-configurable based on user information, application information, background information such as background noise and transducer information such as transducer response characteristics to provide users with alternate input modes to keyboard text entry. Word recognition lattices are generated for each data field of an application and dynamically concatenated into a single word recognition lattice. A language model is applied to the concatenated word recognition lattice to determine the relationships between the word recognition lattices and repeated until the generated word recognition lattices are acceptable or differ from a predetermined value only by a threshold amount. These techniques of dynamic re-configurable speech recognition provide for deployment of speech recognition on small devices such as mobile phones and personal digital assistants as well environments such as office, home or vehicle while maintaining the accuracy of the speech recognition.

Abstract: The present disclosure provides conjugate structures and hydrazinyl-pyrrolo compound structures used to produce these conjugates. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.

Abstract: The technology relates generally to the field of immunology and relates in part to compositions and methods for controlling the proliferation of T cells, for example, therapeutic T cells. The methods further relate to compositions and methods for inducing an immune response in a subject.